Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9711MR)

This product GTTS-WQ9711MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9711MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6870MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ8737MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ480MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ12563MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ2332MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ3983MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ635MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ12491MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW